BIOMAT Database Logo BIOMAT Database Logo

Biological Response Modifier in Cancer Immunotherapy. 2016

Ronghua Liu, and Feifei Luo, and Xiaoming Liu, and Luman Wang, and Jiao Yang, and Yuting Deng, and Enyu Huang, and Jiawen Qian, and Zhou Lu, and Xuechao Jiang, and Dan Zhang, and Yiwei Chu
Department of Immunology, Key Laboratory of Medical Molecular Virology of MOE/MOH, School of Basic Medical Sciences, Fudan University, No.138, Yi Xue Yuan Rd., mail box 226, Shanghai, 200032, People's Republic of China.

Biological response modifiers (BRMs) emerge as a lay of new compounds or approaches used in improving cancer immunotherapy. Evidences highlight that cytokines, Toll-like receptor (TLR) signaling, and noncoding RNAs are of crucial roles in modulating antitumor immune response and cancer-related chronic inflammation, and BRMs based on them have been explored. In particular, besides some cytokines like IFN-α and IL-2, several Toll-like receptor (TLR) agonists like BCG, MPL, and imiquimod are also licensed to be used in patients with several malignancies nowadays, and the first artificial small noncoding RNA (microRNA) mimic, MXR34, has entered phase I clinical study against liver cancer, implying their potential application in cancer therapy. According to amounts of original data, this chapter will review the regulatory roles of TLR signaling, some noncoding RNAs, and several key cytokines in cancer and cancer-related immune response, as well as the clinical cases in cancer therapy based on them.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D009163 Mycobacterium bovis The bovine variety of the tubercle bacillus. It is called also Mycobacterium tuberculosis var. bovis. BCG,Calmette-Guerin Bacillus
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077271 Imiquimod A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS. 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine,Aldara,R 837,R-837,S 26308,S-26308,Zyclara,R837
D000634 Aminoquinolines Quinolines substituted in any position by one or more amino groups.
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

Ronghua Liu, and Feifei Luo, and Xiaoming Liu, and Luman Wang, and Jiao Yang, and Yuting Deng, and Enyu Huang, and Jiawen Qian, and Zhou Lu, and Xuechao Jiang, and Dan Zhang, and Yiwei Chu
[Clinical value of immunotherapy for gynecological cancer by BRM (biological response modifier)].
June 1985, Nihon Sanka Fujinka Gakkai zasshi,
Ronghua Liu, and Feifei Luo, and Xiaoming Liu, and Luman Wang, and Jiao Yang, and Yuting Deng, and Enyu Huang, and Jiawen Qian, and Zhou Lu, and Xuechao Jiang, and Dan Zhang, and Yiwei Chu
Biological response modifier--immunotherapeutic approaches in pancreatic cancer.
December 1989, Hepato-gastroenterology,
Ronghua Liu, and Feifei Luo, and Xiaoming Liu, and Luman Wang, and Jiao Yang, and Yuting Deng, and Enyu Huang, and Jiawen Qian, and Zhou Lu, and Xuechao Jiang, and Dan Zhang, and Yiwei Chu
Melatonin as biological response modifier in cancer patients.
January 1998, Anticancer research,
Ronghua Liu, and Feifei Luo, and Xiaoming Liu, and Luman Wang, and Jiao Yang, and Yuting Deng, and Enyu Huang, and Jiawen Qian, and Zhou Lu, and Xuechao Jiang, and Dan Zhang, and Yiwei Chu
Ozontherapy as a Possible Biological Response Modifier in Cancer.
April 1998, Forschende Komplementarmedizin,
Ronghua Liu, and Feifei Luo, and Xiaoming Liu, and Luman Wang, and Jiao Yang, and Yuting Deng, and Enyu Huang, and Jiawen Qian, and Zhou Lu, and Xuechao Jiang, and Dan Zhang, and Yiwei Chu
The ideal biological response modifier.
January 1989, Molecular biotherapy,
Ronghua Liu, and Feifei Luo, and Xiaoming Liu, and Luman Wang, and Jiao Yang, and Yuting Deng, and Enyu Huang, and Jiawen Qian, and Zhou Lu, and Xuechao Jiang, and Dan Zhang, and Yiwei Chu
Biological-response modifier--induced emergencies.
December 1989, Seminars in oncology,
Ronghua Liu, and Feifei Luo, and Xiaoming Liu, and Luman Wang, and Jiao Yang, and Yuting Deng, and Enyu Huang, and Jiawen Qian, and Zhou Lu, and Xuechao Jiang, and Dan Zhang, and Yiwei Chu
[Sparassis crispa as biological response modifier].
October 2004, Gan to kagaku ryoho. Cancer & chemotherapy,
Ronghua Liu, and Feifei Luo, and Xiaoming Liu, and Luman Wang, and Jiao Yang, and Yuting Deng, and Enyu Huang, and Jiawen Qian, and Zhou Lu, and Xuechao Jiang, and Dan Zhang, and Yiwei Chu
[Lincosamine as indirect biological response modifier].
March 1992, Zeitschrift fur arztliche Fortbildung,
Ronghua Liu, and Feifei Luo, and Xiaoming Liu, and Luman Wang, and Jiao Yang, and Yuting Deng, and Enyu Huang, and Jiawen Qian, and Zhou Lu, and Xuechao Jiang, and Dan Zhang, and Yiwei Chu
Pidotimod. A new biological response modifier. Introduction.
December 1994, Arzneimittel-Forschung,
Ronghua Liu, and Feifei Luo, and Xiaoming Liu, and Luman Wang, and Jiao Yang, and Yuting Deng, and Enyu Huang, and Jiawen Qian, and Zhou Lu, and Xuechao Jiang, and Dan Zhang, and Yiwei Chu
[Intratumoral injection of biological response modifier (BRM)].
September 1991, Nihon Geka Gakkai zasshi,
Copied contents to your clipboard!